Trials / Completed
CompletedNCT02244268
Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia
Effect of ALNA® (Tamsulosin) on the Primary Symptoms of BPH (Benign Prostatic Hyperplasia) Syndrome
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,629 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The aims of this observational study are to identify the primary BPH symptoms responsible for the patients to consult a urologic practice, resulting in the prescription of ALNA®, to assess the clincial efficacy on an improved occupational performance of the patients being still employed. Additionally to obtain relevant information for the 5-year report of experience with this product according to the requirements in § 49, para 6 of the German Medicines Act.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALNA® |
Timeline
- Start date
- 2000-10-01
- Primary completion
- 2001-12-01
- First posted
- 2014-09-19
- Last updated
- 2014-09-19
Source: ClinicalTrials.gov record NCT02244268. Inclusion in this directory is not an endorsement.